Skip to main content

Aytu BioScience, Inc. (AYTU)

NASDAQ: AYTU · IEX Real-Time Price · USD
2.46 -0.10 (-3.91%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap67.79M
Revenue (ttm)65.63M
Net Income (ttm)-58.29M
Shares Out16.75M
EPS (ttm)-3.48
PE Ration/a
Forward PE10.70
Dividendn/a
Ex-Dividend Daten/a
Volume346,402
Open2.58
Previous Close2.56
Day's Range2.39 - 2.58
52-Week Range2.39 - 11.76
Beta-0.18
AnalystsBuy
Price Target17.50 (+611.4%)
Est. Earnings DateNov 9, 2021

About AYTU

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine...

IndustryPharmaceuticals
Employees175
Stock ExchangeNASDAQ
Ticker SymbolAYTU
Full Company Profile

Financial Performance

In 2021, AYTU's revenue was $65.63 million, an increase of 137.52% compared to the previous year's $27.63 million. Losses were -$58.29 million, 327.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for AYTU stock is "Buy." The 12-month stock price forecast is 17.50, which is an increase of 611.38% from the latest price.

Price Target
$17.50
(611.38% upside)
Analyst Consensus: Buy

News

ALERT: Rowley Law PLLC is Investigating Potential Breaches of Fiduciary Duty by the Aytu BioPharma, Inc. Board of Dir...

NEW YORK, Oct. 4, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating a potential breach of fiduciary duty claim involving the board of directors of Aytu BioPharma, Inc. (NASDAQ: AYTU). If you are a s...

2 weeks ago - PRNewsWire

CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences

(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST) ENGLEWOOD, CO / ACCESSWIRE / September 30, 2021 ...

3 weeks ago - Accesswire

Recap: Aytu BioPharma Q4 Earnings

Aytu BioPharma(NASDAQ:AYTU) stock fell by 8.33% on Tuesday after the company reported its Q4 earnings results on Monday, September 27, 2021 at 04:01 PM. Here's what investors need to know about the anno...

3 weeks ago - Benzinga

Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results

Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M Ended quarter with approximately $50M in cash, cash equivalents and restricted cash Planned pivotal study for AR...

3 weeks ago - Accesswire

Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27...

ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, a...

1 month ago - Accesswire

Aytu BioPharma to Present at Upcoming September Investor Conferences

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, an...

1 month ago - Accesswire

2 Falling Knives to Catch

Unexpectedly, Wall Street recommends acquiring shares of Hycroft Mining Holding Corp ( HYMC , Financial) and Aytu BioPharma Inc ( AYTU , Financial), even though these two stocks have shown poor performa...

Other symbols:HYMC
2 months ago - GuruFocus

Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from...

ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announ...

2 months ago - Accesswire

Implied Volatility Surging for Aytu Biopharma (AYTU) Stock Options

Investors need to pay close attention to Aytu Biopharma (AYTU) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study

Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19 P...

3 months ago - Accesswire

Technical Levels To Watch In Aytu BioPharma Stock

Aytu BioPharma Inc. (NASDAQ: AYTU) shares were rallying Monday after retail traders were able to push the stock higher. The stock has traded on above-average volume with 7.6 million shares traded so far...

4 months ago - Benzinga

What's Next For Aytu BioPharma Stock As It Gaps Up To Resistance?

Aytu BioPharma Inc. (NASDAQ: AYTU) shares saw a gap up Tuesday morning as retail traders tried to push the stock higher. The stock saw a sizable premarket move and opened at $6.15, but has since fallen ...

4 months ago - Benzinga

Aytu BioPharma to Present at Upcoming June Investor Conferences

ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announc...

4 months ago - Accesswire

Recap: Aytu BioPharma Q3 Earnings

Shares of Aytu BioPharma (NASDAQ:AYTU) decreased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 186.67% year over year to ($0.43), which missed ...

5 months ago - Benzinga

Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights

- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isof...

5 months ago - Accesswire

Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial...

ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announc...

5 months ago - Accesswire

Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021

ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announc...

5 months ago - Accesswire

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome ...

6 months ago - Accesswire

5 Stocks to Buy on New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

Other symbols:ASYSCDMOIBKRONCT
6 months ago - Zacks Investment Research

Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer

ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today ...

6 months ago - Accesswire

Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma

Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics ENGLEWOOD, CO / ACCESSWIRE / April 1...

6 months ago - Accesswire

10 Reddit Penny Stocks Seeing the Most Chatter Today

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on...

7 months ago - InvestorPlace

Aytu BioScience Announces Close of Merger with Neos Therapeutics

$100M revenue specialty pharmaceutical company on an accelerated path to profitability[1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth ...

7 months ago - Accesswire

Why Did Aytu Biosciences Gap Up Today? Technical Levels To Watch

Aytu Biosciences Inc. (NASDAQ: AYTU) shares gapped up Thursday morning. The price jump is speculatively from the meetings the company is having about the proposed merger with Neos Therapeutics Inc. (NAS...

7 months ago - Benzinga

Merger News: Why NEOS Stock and AYTU Stock Are Climbing Today

NEOS stock holders will get AYTU stock in this no-cash merger transaction. Today's vote has the support of two proxy advisory firms.

7 months ago - InvestorPlace